INOVIQ Ltd

Equities

IIQ

AU0000196149

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 10:31:33 28/05/2024 am IST			5-day change	1st Jan Change
0.48 ^AUD	-2.04%		-2.04%	-27.82%

19/04	INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test	MT
15/04	Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares	MT

Dr. Irmgard Irminger-Finger Steps Down from Board of BARD1 Life Sciences Limited

January 15, 2021 at 04:14 am IST

BARD1 Life Sciences Limited announced that Dr. Irmgard Irminger-Finger has stepped down from the board. Dr. Irminger-Finger will continue to provide scientific expertise and technical support to BARD1 technology programs, the technology she originally invented, with a focus on advancing the development of its BARD1 autoantibody tests.

Latest news about INOVIQ Ltd

INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test	19/04	MT
Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares	15/04	MT
INOVIQ Signs Supply, Distribution Agreement with Promega; Shares Surge 18%	15/04	MT
Inoviq's Test Detects 19% More Breast Cancers Than Market Leader	23/02	MT
INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	23/02	CI
Inoviq Appoints Chair Elect; Shares Climb 13%	11/23/11	MT
Inoviq Signs Deal for Use of Biomarker Capture Product in the US	05/23/05	MT
INOVIQ Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
INOVIQ Limited and Promega Corporation Announce Global Joint Marketing Agreement for EXO-NET Exosome Isolation and Nucleic Acid Purification Solutions	06/23/06	CI
Inoviq Signs Global Marketing Deal for Exosome Technology	06/23/06	MT
Inoviq Limited Announces Clinical Validation Study for Subb2m/Ca15-3 Breast Cancer Test	27/23/27	CI
Inoviq Confirms Efficacy of Breast Cancer Test	27/23/27	MT
INOVIQ Limited to Present New Exo-NET Data at ISEV Annual Meeting	19/23/19	CI
INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24	CI
INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24	CI
Inoviq's Breast Cancer Diagnostic Test Outdoes Commercial Test in Independent Study	08/23/08	MT
INOVIQ Limited Announces Positive Results for SubB2M Breast Cancer Test	08/23/08	CI
INOVIQ Ltd Announces Resignation of Professor Allan Cripps AO as Director	14/22/14	CI
INOVIQ's Ovarian Cancer Detection Kits Up to 90% Accurate, Study Says	13/22/13	MT
INOVIQ Limited Announces the Ovarian Cancer 97 Study Completed by the Centre for Clinical Research	13/22/13	CI
Inoviq Advances Commercial Sales of Medical Products in the US; Moves Research Facility to Australia	25/22/25	MT
Inoviq Gets Canadian Patent for Lung Cancer Diagnosis Technology	27/22/27	MT
Inoviq Receives nearly $550,000 R&D Tax Refund in FY21; Shares Jump 7%	14/22/14	MT
INOVIQ to Test SubB2M Technology in Canadian Instrument	13/22/13	MT
Genetic Technologies Appoints CFO; Shares Plunge 25%	10/22/10	MT

Chart INOVIQ Ltd

Duration

Period

More charts

Company Profile

INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INOVIQ LTD	-27.82%	30.02M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research

INOVIQ Ltd

Equities

IIQ

AU0000196149

Biotechnology & Medical Research

Dr. Irmgard Irminger-Finger Steps Down from Board of BARD1 Life Sciences Limited

Latest news about INOVIQ Ltd

Chart INOVIQ Ltd

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research